New Series Alert! Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, leads a panel discussion about CDK4/6 inhibitor use in high-risk early breast cancer with experts Naomi Dempsey, MD; Joyce O'Shaughnessy, MD; and Hope S. Rugo, MD, FASCO. Tune in to learn about trial updates, best practices in managing toxicity profiles, and financial challenges to navigate while optimizing patient outcomes. Watch here: https://bit.ly/4eGWTru #BreastCancer #ManagedCare
AJMC - The American Journal of Managed Care’s Post
More Relevant Posts
-
We want to call your attention to a timely new series on AJMC® Peer Exchange® peer-to-peer panel discussions featuring authoritative insights, opinions, and perspectives on important issues facing today’s managed care professionals. Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, leads an expert panel discussion on the use of CDK4/6 inhibitors in high-risk early breast cancer. With insights from renowned experts Naomi Dempsey, MD; Joyce O'Shaughnessy, MD; and Hope S. Rugo, MD, FASCO, this series covers crucial updates, best practices in managing toxicity profiles, and navigating financial challenges to optimize patient outcomes. Don't miss out on this opportunity to learn about: - Factors influencing decisions to prescribe CDK4/6 inhibitors - Analysis of the monarchE and NATALEE trial results - Sequencing considerations with CDK4/6 inhibitors - Differences in toxicity profiles between abemaciclib and ribociclib - The impact of different endocrine therapies on toxicities Watch the series here: https://bit.ly/4eGWTru #BreastCancer #ManagedCare #CDK46Inhibitors #Oncology #PatientCare #MedicalUpdates
New Series Alert! Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, leads a panel discussion about CDK4/6 inhibitor use in high-risk early breast cancer with experts Naomi Dempsey, MD; Joyce O'Shaughnessy, MD; and Hope S. Rugo, MD, FASCO. Tune in to learn about trial updates, best practices in managing toxicity profiles, and financial challenges to navigate while optimizing patient outcomes. Watch here: https://bit.ly/4eGWTru #BreastCancer #ManagedCare
Advances in CDK4/6 Inhibitor Use in High-Risk Early Breast Cancer: 2024 Updates
ajmc.com
-
Board Ready Biopharma Executive | Executive Vice President | Chief Development Officer | Global Head of Nonclinical R&D | Early Development Franchise Leader | Serial Operational Builder | CLS FAST Strategic Advisor
Don't miss out on this opportunity to learn about: - Factors influencing decisions to prescribe CDK4/6 inhibitors - Analysis of the monarchE and NATALEE trial results - Sequencing considerations with CDK4/6 inhibitors - Differences in toxicity profiles between abemaciclib and ribociclib - The impact of different endocrine therapies on toxicities Watch the series here: https://bit.ly/4eGWTru #BreastCancer #ManagedCare #CDK46Inhibitors #Oncology #PatientCare #MedicalUpdates
New Series Alert! Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, leads a panel discussion about CDK4/6 inhibitor use in high-risk early breast cancer with experts Naomi Dempsey, MD; Joyce O'Shaughnessy, MD; and Hope S. Rugo, MD, FASCO. Tune in to learn about trial updates, best practices in managing toxicity profiles, and financial challenges to navigate while optimizing patient outcomes. Watch here: https://bit.ly/4eGWTru #BreastCancer #ManagedCare
Advances in CDK4/6 Inhibitor Use in High-Risk Early Breast Cancer: 2024 Updates
ajmc.com
-
SENIOR MARKETING LEADER | MARKETING STRATEGY | CHANGE MANAGEMENT | DIGITAL TRANSFORMATION
🎤 Join our live discussion today at 6pm CET! 🎥 Live session with Prof. Roman Rouzier and Dr Delphine Hequet 👨⚕️ Looking at the cost effectiveness and real-world cost savings associated with using #Prosigna in eligible early stage #breastcancer patients. #moleculardiagnostics #breastoncology #Veracyte #Prosigna
Join us tonight for a live discussion with leading #BreastCancer experts moderated by Martin Bostrup, PhD (Sr. Director of Market Access, IVD Services, at Veracyte). This webinar will explore the cost-effectiveness and real-world cost savings associated with using Veracyte's Prosigna Breast Cancer Assay in eligible patients with early breast cancer. We look forward to seeing you there! https://lnkd.in/e5fRuWty
-
-
Focusing on HER2+ breast cancer
Focusing on HER2+ breast cancer, Erika P. Hamilton, MD, and the Oncology Brothers review data from JBCRG-M06/EMERALD looking at trastuzumab and pertuzumab in combination with eribulin or a taxane in locally advanced or metastatic disease. #BCSM #ASCO24 https://lnkd.in/eXsdHsD3
Recent Data from JBCRG-M06/EMERALD in HER2+ Breast Cancer
targetedonc.com
-
Explore strategies with our On-Demand Video featuring breast cancer experts | Adjuvant Endocrine Therapy in HR+ Breast Cancer: Enhancing Quality Care and Patient Outcomes | 0.5-hour CME/CE | #MedEd #cme #HR+breastcancer | https://bit.ly/495OtG3
-
-
Explore strategies with our On-Demand Video featuring breast cancer experts | Adjuvant Endocrine Therapy in HR+ Breast Cancer: Enhancing Quality Care and Patient Outcomes | 0.5-hour CME/CE | #MedEd #cme #HR+breastcancer | https://bit.ly/495OtG3
-
-
Explore strategies with our On-Demand Video featuring breast cancer experts | Adjuvant Endocrine Therapy in HR+ Breast Cancer: Enhancing Quality Care and Patient Outcomes | 0.5-hour CME/CE | #MedEd #cme #HR+breastcancer | https://bit.ly/495OtG3
-
-
Novartis at #ESMOBreast24 Visit poster 277P presented by Dr. Nadia Harbeck to learn more about our results on a descriptive analysis of hepatic safety in patients with HR+/HER2- breast cancer. https://lnkd.in/dgyBz9py #Novartis #BreastCancer
-
-
Explore strategies with our On-Demand Video featuring breast cancer experts | Adjuvant Endocrine Therapy in HR+ Breast Cancer: Enhancing Quality Care and Patient Outcomes | 0.5-hour CME/CE | #MedEd #cme #HR+breastcancer | https://bit.ly/495OtG3
-
-
In a case study conducted by Briya at a leading hospital, it was discovered that 21% of patients had missing information regarding receptor status. This finding is just one of many valuable insights revealed by Briya’s #MedicalData network on the treatment of early-stage, high-risk breast cancer. Our latest case study delves into the complete patient journey, from diagnosis to treatment, providing a profound understanding of the correlation between the patient journey and success rates. Read the full case study here: https://lnkd.in/dHrEtMmY
-
